drugset
drugset / Trial / NCT01842646

Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS)

NCT01842646 ↗

Phase 2 Completed 35 enrolled H. Lee Moffitt Cancer Center and Research Institute Pfizer · collab
NaSingle-groupOpen-labelTreatment

Summary

This study is being done to see how safe an investigational drug is and test how well it will work to help people with refractory/relapsed myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML).

Timeline

Start
2013-08-29
Primary completion
2016-01-31
Completion
2021-06-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Glasdegib Small molecule 50 mg Oral
Subject Glasdegib Small molecule 100 mg Oral
Subject Glasdegib Small molecule 200 mg Oral

Indications

chronic myelomonocytic leukemia myelodysplastic syndrome